Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT
· Real-Time Price · USD
24.28
-3.74 (-13.35%)
At close: May 06, 2025, 3:59 PM
24.71
1.77%
Pre-market: May 07, 2025, 05:01 AM EDT
-13.35% (1D)
| Bid | 24.7 |
| Market Cap | 17.91B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -240.75M |
| EPS (ttm) | -0.34 |
| PE Ratio (ttm) | -71.41 |
| Forward PE | -57.14 |
| Analyst | Buy |
| Ask | 24.8 |
| Volume | 3,949,278 |
| Avg. Volume (20D) | 4,001,020 |
| Open | 27.00 |
| Previous Close | 28.02 |
| Day's Range | 23.80 - 27.09 |
| 52-Week Range | 2.10 - 36.91 |
| Beta | -0.46 |
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, fo...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 5, 2015
Employees 159
Stock Exchange NASDAQ
Ticker Symbol SMMT
Website https://www.summittxinc.com
Analyst Forecast
According to 11 analyst ratings, the average rating for SMMT stock is "Buy." The 12-month stock price forecast is $37.5, which is an increase of 54.45% from the latest price.
Stock Forecasts1 week ago
-36.05%
Summit Therapeutics shares are trading lower. The ...
Unlock content with
Pro Subscription
2 weeks ago
+21.5%
Summit Therapeutics shares are trading higher after the company provided updates on its Phase 3 trial of Ivonescimab and announced it met its primary endpoint.
